What Regumate Equine Treats: Main Uses and Benefits

Regumate Equine (Altrenogest) is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed for reproductive management in mares. The primary applications are relevant for easing symptoms related to estrus.

---

The medication is commonly used to help with establishing predictable cycle timing, which assists with maintaining functional stability for daily management and supporting the planning needs of breeding programs. This is relevant for managing symptoms that interfere with daily comfort, such as erratic or prolonged estrous periods and the undesirable mood changes associated with heat. In specialized contexts, it may be part of symptomatic management when a mare experiences conditions involving episodic or fluctuating manifestations linked to low progestin levels, offering supportive relief.

“It is commonly used to help with establishing predictable cycle timing for mares in breeding and performance programs.”

Quick Fact: Supportive Management of Irregular Estrous Symptoms

Key Symptomatic Support Areas

The primary symptomatic support areas include managing irregularity of the estrous cycle, managing symptoms of undesirable behavior associated with heat during performance periods, and providing supportive therapy in at-risk pregnancies. The support provided helps improve day-to-day comfort, assists with maintaining functional stability, and is relevant for easing symptoms that interfere with routine activities during training and competition.

Regulatory References

1. FDA DailyMed overview of Altrenogest

Eligibility Scope for Regumate Equine (Altrenogest)

Regumate Equine is exclusively a veterinary medicine and its official eligibility is defined by the target animal and strict exclusions for both horses and human handlers.

Classification	Population Rule (Official Labeling)
Approved Target	Mares (female horses) for reproductive management and estrus suppression.
Contraindicated (Equine)	Mares with a current or previous history of uterine inflammation (endometritis).
Contraindicated (Human)	Pregnant women or women who may be pregnant (must not handle the solution).
Restricted Handling	Women of childbearing age must exercise extreme caution due to the risk of dermal absorption of the progestin.
Excluded Groups	Humans (not for use), Stallions or Geldings (male horses), and horses intended for human consumption.

Eligibility is primarily limited to adult mares to facilitate a predictable estrus cycle. Use in non-target species is strictly prohibited. Furthermore, the high hormonal potency of the solution requires that certain human populations, including those with a history of blood clots, liver disease, or hormone-dependent tumors, must avoid all contact due to the risk of systemic absorption.

Interactions with other medicines and products

The regulatory profile for Regumate Equine (Altrenogest) provides specific information regarding interactions with other substances, based strictly on official governmental documentation. This section details the known co-administration restrictions and the classification of interaction severity.

Documented Medicinal Product Interactions

The official prescribing information for Altrenogest documents a specific interaction risk with the antifungal medicine Griseofulvin. Co-administration with Griseofulvin is formally noted as a restriction because it may alter the effects of Altrenogest. This is the only medicinal product explicitly listed in regulatory interaction statements for the mare.

Interaction Context	Documented Restriction
Specific Interacting Medicine	Griseofulvin
Official Outcome	May alter the effects of Altrenogest

Other Interaction Considerations

Specific mechanisms underlying potential interactions, such as those related to CYP-mediated metabolic pathways or drug transporters, are not explicitly documented in the official regulatory labels. Furthermore, the official pharmaceutical particulars state that no major incompatibilities are known for the Altrenogest oral solution. There are no mandatory timing separation rules (e.g., "administer X hours apart") or specific interaction considerations for different populations documented in the prescribing information. The overall interaction profile is characterized by its high specificity, focusing on the single documented co-administration risk.

How Regumate Equine Works

Progesterone Receptor Agonism

The mechanism begins with Altrenogest acting as a high-affinity agonist at the intracellular Progesterone Receptor (PR), found in reproductive tissues, the hypothalamus, and the pituitary gland. This interaction creates a sustained, high-level progestational signal characteristic of the natural luteal phase.

---

Central Endocrine Axis Suppression

This sustained signal exerts a powerful negative feedback on the central Hypothalamic-Pituitary-Gonadal (HPG) axis. This action directly suppresses the necessary pulsatile release of Gonadotropin-Releasing Hormone (GnRH), which, in turn, inhibits the pituitary's secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

---

Physiological Consequence: Temporary Quiescence

The suppression of gonadotropin release prevents the final LH surge required for ovulation and stabilizes the ovarian follicle development. This mechanism leads to a state of temporary hormonal quiescence and concurrently modulates the central nervous system pathways involved in estrus behavior.

Administration Route and Dosing

Regumate Equine is prescribed as an oral solution containing 2.2 mg of the active ingredient Altrenogest per mL of solution. The administration is strictly by the oral route. The correct daily dosage is precisely calculated based on the animal’s weight, requiring 0.044 mg of Altrenogest per kg of body weight. This calculation corresponds to administering 1 mL for every 110 pounds of body weight. The solution must be accurately measured using a specialized luer lock syringe or approved dosing device to ensure precision and compliance with labeling requirements.

Frequency and Treatment Duration

The medication is administered once daily. The duration of the continuous daily treatment course varies depending on the regulatory region. In the United States, the established protocol requires administration for 15 consecutive days. In contrast, certain European regulatory documents specify a continuous treatment course of 10 consecutive days. Adherence to the daily dosing schedule is essential to maintain the intended physiological outcome defined in the regulatory authorization.

Official Delivery Method

The measured dose is intended to be delivered either directly onto the base of the mare’s tongue or mixed uniformly into the animal’s usual grain ration. When the dose is combined with feed, regulatory instructions specify that the medicated feed must be offered at a single feeding per day. Furthermore, the medicated feed should be consumed immediately after preparation and must not be stored for later use, requiring safe destruction of any residual amounts. The regimen is established for use exclusively in mares.

Research Evidence / Overview of Studies for Regumate Equine

This section describes the official research evidence, primarily Controlled Clinical Trials, studied to support the medicine’s approved indications for reproductive management, as reviewed by regulatory authorities. The findings reported here reflect the specific conditions and populations studied, providing context but not individual predictions.

---

Evidence for Use in Estrus Cycle Suppression

Clinical research, including Controlled Clinical Trials and Field Studies, was evaluated in non-pregnant mares. These trials were used in research exploring how symptoms change over time related to the behavioral signs of heat. The trials monitored and reported measurements of outcomes related to estrus cessation within the observed populations. Findings describe patterns observed in the studies, characterizing measured outcomes related to episodic or acute changes in estrus behavior.

Long-Term Data and Follow-Up in Research

Long-term outcomes are not well characterized in the regulatory research base. Follow-up durations were limited in the core regulatory studies, and there is limited information for long-term outcomes regarding the overall durability or maintenance of consistent reproductive stability across multiple, subsequent seasons.

---

Evidence for Use in Reproductive Cycle Synchronization

The medicine was studied for its use in synchronization, a research scenario applied in studies examining patient-reported experiences related to fertility planning. Researchers monitored the predictability of when estrus would resume and the subsequent time interval until ovulation occurred. Findings indicate patterns where a predictable return to estrus and a concentration of subsequent ovulation events was observed in some studies. This research contributes to the broader evidence landscape regarding short-term changes.

---

Research Gaps and Remaining Uncertainty

The evidence highlights what is known — and what is still uncertain — about the research base. The main evidence gaps and limitations documented in regulatory and scientific literature include the lack of robust data on long-term effects, as follow-up durations were limited. Furthermore, the data for certain groups remain insufficient, meaning the certainty remains low when the drug was studied for cycle synchronization in mares with low or inactive ovarian function. The results apply only to the populations studied in the original regulatory trials.

Key Studies & References

1. Altrenogest Oral Solution Label: Indications, Clinical Studies, and Limitations (DailyMed)

Common questions about Regumate Equine (FAQ)

Q: Does this product make you sleepy?

A: Official product information and studies indicate that drowsiness and somnolence (sleepiness) are common effects reported for some regulated melatonin products. Patients using the product should be aware that reduced alertness may occur. This is noted in official regulatory documents.

Q: Can I drink alcohol while taking this?

A: Regulatory documents explicitly advise that alcohol should not be taken when using this product. The official product information states that alcohol can reduce the intended effects of the product on sleep. The official guidance states that avoiding alcohol consumption may help ensure the full benefit of the product.

Q: Is this safe to use during pregnancy or breastfeeding?

A: It is generally advised to avoid the use of this product during pregnancy as a measure of precaution. Since it is unknown how this product may affect a newborn or infant, the official information indicates that a healthcare professional should be consulted if planning to use the product while pregnant or breastfeeding.

Q: What are the proper storage conditions?

A: According to the official product label, this medication should typically be stored in a cool, dry place. The temperature should not exceed 25°C (77°F), and it should be kept away from light and direct heat. It is important to refer to the specific storage instructions provided on the product packaging.

Q: Can children 2 years old use it?

A: The use of this product in children is based on specific regulations for each formulation. Some official product labels specify use is indicated for children 2 years and older, while others may be restricted to older ages, or carry general cautions regarding use in pediatric populations. Patients should check the age guidelines provided on the specific product package, or consult a healthcare professional for guidance.

How to Store and Dispose of Regumate Equine?

The storage and disposal of Regumate Equine (Altrenogest) are subject to official regulatory requirements to ensure product integrity and safety.

Official Storage and Stability

Condition Type	Requirement
Temperature	Store at or below 25°C (77°F). Do not freeze.
Packaging	Must be kept in the original container with the cap tightly sealed.
Stability	Shelf-life after first opening is strictly limited to 14 days (150 ml size) or 28 days (larger sizes).
Protection	Keep out of the sight and reach of children and other animals.

Mandatory Disposal and Handling

Unused or expired product must be disposed of according to local pharmaceutical waste regulations, typically using take-back schemes. The active ingredient, Altrenogest, is environmentally toxic, and the solution must not enter water courses or be disposed of via wastewater. Due to the risk of absorption, vinyl, neoprene, or nitrile gloves are mandatory when handling the solution to prevent skin contact.